Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
OTHER OTC:GNFT
GNFT Stock Chart & Stats
$5.42
-$0.06(-1.61%)
At close: 4:00 PM EST
$5.42
-$0.06(-1.61%)
Day’s Range― - ―
52-Week Range$2.55 - $5.88
Previous CloseN/A
Volume1.39K
Average Volume (3M)12.15K
Market Cap
$219.11M
Enterprise Value$222.30M
Total Cash (Recent Filing)$107.51M
Total Debt (Recent Filing)$138.91M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Apr 09, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding50,024,750
10 Day Avg. Volume22,771
30 Day Avg. Volume12,154
Financial Highlights & Ratios
PEG Ratio-1.14
Price to Book (P/B)2.61
Price to Sales (P/S)2.69
P/FCF Ratio12.69
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.37
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda-9.56
Forecast
1Y Price Target
$7.50Price Target Upside38.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$83.65M
Bulls Say, Bears Say
Bulls Say
Financial StabilityGenfit remains well capitalized, with a cash runway beyond 2028, providing financial stability and potential for future growth.
Market LeadershipDespite the VS-01 discontinuation, Genfit remains the clear industry leader in ACLF, showcasing its strong position in the market.
Pipeline OpportunitiesThe pipeline includes four additional programs with differentiated mechanisms of action, offering diversified exposure to a multibillion-dollar market with no approved therapies.
Bears Say
Clinical SetbackThe discontinuation of VS-01 in ACLF followed a serious adverse event of peritonitis, making VS-01 unsuitable for ACLF patients.
Near Term HeadwindThe discontinuation of VS-01 in ACLF is a near term headwind due to the fragile ICU patient population and elevated infection risk.
Genfit SA News
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $2.55 and its highest was $5.88 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $219.11M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 09, 2026 which is in 110 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 22, 2025. The company reported -$0.236 earnings per share for the quarter, missing the consensus estimate of $1.192 by -$1.428.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.28.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,024,750 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -$0.236 in its last earnings report, missing expectations of $1.192. Following the earnings report the stock price went down -12.53%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genfit SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.52%
12-Months-Change
Fundamentals
Return on Equity
-51.06%
Trailing 12-Months
Asset Growth
22.06%
Trailing 12-Months
Company Description
Genfit SA
Genfit SA (GNFT) is a biopharmaceutical company based in France that specializes in the development of innovative therapeutic solutions for metabolic and liver diseases. The company focuses on precision medicine and has a strong pipeline of drug candidates targeting conditions such as non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. Genfit also engages in diagnostic services and is committed to advancing research in the field of hepatology.
GNFT Stock 12 Month Forecast
Average Price Target
$7.50
▲(38.38% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---